Effects of Sertraline and Fluoxetine on P-Glycoprotein at Barrier Sites: In Vivo and In Vitro Approaches

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Kapoor, Amita ^a   Iqbal, Majid ^b   Petropoulos, Sophie ^b   Ho, Hay Lam ^b   Gibb, William ^c   Matthews, Stephen G ^b  

^a UNIVERSITY OF WISCONSIN   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CALCEIN; DIGOXIN; FLUOXETINE; MULTIDRUG RESISTANCE PROTEIN; SERTRALINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BLOOD TESTIS BARRIER; BRAIN BLOOD VESSEL; BRAIN CELL; BRAIN TISSUE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; ENDOTHELIUM CELL; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; MALE; MOUSE; NONHUMAN; PROTEIN FUNCTION; TESTIS;

ANIMALS; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; BLOOD-TESTIS BARRIER; ENDOTHELIAL CELLS; FLUOXETINE; GUINEA PIGS; MALE; MICE; P-GLYCOPROTEIN; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; TIME FACTORS;

EID: 84874529448     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0056525     Document Type: Article

References (30)

1. Gros P, Ben Neriah YB, Croop JM, Housman DE, (1986) Isolation and expression of a complementary DNA that confers multidrug resistance. Nature 323: 728-31.
2. Uhr M, Grauer MT, (2003) abcb1ab P-glycoprotein is involved in the uptake of citalopram and trimipramine into the brain of mice. J Psychiatr Res 37: 179-85.
3. Seelig A, (1998) A general pattern for substrate recognition by P-glycoprotein. Eur J Biochem 251: 252-61.
4. Seelig A, Blatter XL, Wohnsland F, (2000) Substrate recognition by P-glycoprotein and the multidrug resistance-associated protein MRP1: a comparison. Int J Clin Pharmacol Ther 38: 111-21.
5. Bansal T, Jaggi M, Khar RK, Talegaonkar S, (2009) Emerging significance of flavonoids as P-glycoprotein inhibitors in cancer chemotherapy. J Pharm Pharm Sci 12: 46-78.
6. Schinkel AH, Wagenaar E, van Deemter L, Mol CA, Borst P, (1995) Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest 96: 1698-705.
7. Sun M, Kingdom J, Baczyk D, Lye SJ, Matthews SG, et al. (2006) Expression of the multidrug resistance P-glycoprotein, (ABCB1 glycoprotein) in the human placenta decreases with advancing gestation. Placenta 27: 602-9.
8. van der Valk P, van Kalken CK, Ketelaars H, Broxterman HJ, Scheffer G, et al. (1990) Distribution of multi-drug resistance-associated P-glycoprotein in normal and neoplastic human tissues. Analysis with 3 monoclonal antibodies recognizing different epitopes of the P-glycoprotein molecule. Ann Oncol 1: 56-64.
9. Cordon-Cardo C, O'Brien JP, Boccia J, Casals D, Bertino JR, et al. (1990) Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 38: 1277-87.
10. Cordon-Cardo C, O'Brien JP, Casals D, Rittman-Grauer L, Biedler JL, et al. (1989) Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci U S A 86: 695-8.
11. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, et al. (1989) Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein. J Histochem Cytochem 37: 159-64.
12. Tsuji A, Terasaki T, Takabatake Y, Tenda Y, Tamai I, et al. (1992) P-glycoprotein as the drug efflux pump in primary cultured bovine brain capillary endothelial cells. Life Sci 51: 1427-37.
13. Bart J, Hollema H, Groen HJ, de Vries EG, Hendrikse NH, et al. (2004) The distribution of drug-efflux pumps, P-gp, BCRP, MRP1 and MRP2, in the normal blood-testis barrier and in primary testicular tumours. Eur J Cancer 40: 2064-70.
14. Loscher W, Potschka H, (2005) Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog Neurobiol 76: 22-76.
15. Luna-Tortos C, Fedrowitz M, Loscher W, (2010) Evaluation of transport of common antiepileptic drugs by human multidrug resistance-associated proteins (MRP1, 2 and 5) that are overexpressed in pharmacoresistant epilepsy. Neuropharmacology 58: 1019-32.
16. Peer D, Dekel Y, Melikhov D, Margalit R, (2004) Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models. Cancer Res 64: 7562-9.
17. Carlson RW, O'Neill AM, Goldstein LJ, Sikic BI, Abramson N, et al. (2006) A pilot phase II trial of valspodar modulation of multidrug resistance to paclitaxel in the treatment of metastatic carcinoma of the breast (E1195): a trial of the Eastern Cooperative Oncology Group. Cancer Invest 24: 677-81.
18. Lhomme C, Joly F, Walker JL, Lissoni AA, Nicoletto MO, et al. (2008) Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer. J Clin Oncol 26: 2674-82.
19. Mayer U, Wagenaar E, Dorobek B, Beijnen JH, Borst P, et al. (1997) Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833. J Clin Invest 100: 2430-6.
20. Uhr M, Grauer MT, Holsboer F, (2003) Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-glycoprotein gene disruption. Biol Psychiatry 54: 840-6.
21. Weiss J, Dormann SM, Martin-Facklam M, Kerpen CJ, Ketabi-Kiyanvash N, et al. (2003) Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther 305: 197-204.
22. Argov M, Kashi R, Peer D, Margalit R, (2009) Treatment of resistant human colon cancer xenografts by a fluoxetine-doxorubicin combination enhances therapeutic responses comparable to an aggressive bevacizumab regimen. Cancer Lett 274: 118-25.
23. Bhuiyan M, Petropoulos S, Gibb W, Matthews SG, (2012) Sertraline alters multidrug resistance phosphoglycoprotein activity in the mouse placenta and fetal blood-brain barrier. Repro Sci 19: 407-415.
24. Iqbal M, Gibb W, Matthews SG, (2011) Corticosteroid regulation of P-glycoprotein in the developing blood-brain barrier. Endocrinology 152: 1067-79.
25. Petropoulos S, Kalabis GM, Gibb W, Matthews SG, (2007) Functional changes of mouse placental multidrug resistance phosphoglycoprotein (ABCB1) with advancing gestation and regulation by progesterone. Reprod Sci 14: 321-8.
26. Endres CJ, Hsiao P, Chung FS, Unadkat JD, (2006) The role of transporters in drug interactions. Eur J Pharm Sci 27: 501-17.
27. Petropoulos S, Gibb W, Matthews SG, (2010) Effect of glucocorticoids on regulation of placental multidrug resistance phosphoglycoprotein (P-gp) in the mouse. Placenta 31: 803-10.
28. Westholm DE, Rumbley JN, Salo DR, Rich TP, Anderson GW, (2008) Organic anion-transporting polypeptides at the blood-brain and blood-cerebrospinal fluid barriers. Curr Top Dev Biol 80: 135-70.
29. Solbach TF, Konig J, Fromm MF, Zolk O, (2006) ATP-binding cassette transporters in the heart. Trends Cardiovasc Med 16: 7-15.
30. Kalabis GM, Petropoulos S, Matthews SG, (2007) Breast cancer resistance protein (Bcrp1/Abcg2) in mouse placenta and yolk sac: ontogeny and its regulation by progesterone. Placenta 10: 1073-81.